Accueil
Marchés
Graphique & Idées
Algo
Nouvelles
Store
Courtiers
Télécharger
Calendrier Economique
Signaux de trading
Terminal Web
Tapez
/
pour rechercher : @user, $symbol
Recherche
Se connecter
Créer un compte
Français
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Italiano
Türkçe
KYMR
#901
Kymera Therapeutics, Inc. Common Stock
91.350
0
+1.44%
Secteur:
Base:
Devise de Profit:
Range quotidien
Range Annuel
Changement quotidien
+1.44%
Changement Mensuel
+25.93%
Evolution sur 6 mois
+54.57%
Changement Annuel
+54.57%
Clôture Précédente
90.050
0
Open
91.380
0
Bid
Ask
Low
91.350
0
High
91.380
0
Volume
150
Marchés
Actions des Marchés US
Soins de Santé
KYMR
Open full chart
Financials
Overview
Relevé
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
44.81 M
51.7 M
55.18 M
61.11 M
64.94 M
81.64 M
—
Valuation ratios
Enterprise value
2.75 B
3.23 B
1.3 B
1.44 B
2.49 B
6 B
14.43 B
Price to earnings ratio
—
—
-8.66
-10.06
-13.5
-21.09
-58.15
Price to sales ratio
—
—
28.61
18.83
64.14
—
—
Price to cash flow ratio
—
—
-8.75
-14.39
-15.52
28.23
-13.71
Price to book ratio
—
—
2.73
3.75
3.61
4.16
7.04
Enterprise value to EBITDA ratio
—
—
—
—
-8.27
—
—
Profitability ratios
Return on assets %
0.09
0.17
0.26
0.26
0.23
0.18
0.26
Return on equity %
0.16
0.22
0.32
0.37
0.27
0.2
0.3
Return on invested capital %
65.97
160.54
290.93
—
—
199.2
—
Gross margin %
100
100
100
100
0
0
0
Operating margin %
136.05
138.03
344.37
210.62
555.82
891.07
7 830.73
EBITDA margin %
—
—
—
—
-640.16
-969.87
-8 054.78
Net margin %
133.96
137.6
330.6
186.99
475.57
794.04
6 967.04
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
2.73
4.88
5.88
4.73
7.53
10.47
34.66
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0.07
0.13
0.08
0.13
0.06
0.03
0.04
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
—
2.84
1.76
2.59
2.76
2.83
EBIT per share
—
—
—
—
-4.11
-4.6
-4.68
EBITDA per share
—
—
—
—
-4.02
-4.5
-4.58
Total debt per share
—
—
—
—
—
—
—
Cash per share
—
—
7.55
6.42
6.51
10.04
29.88
Net current asset value per share
—
—
7.78
6.94
6.8
10.31
31.67
Tangible book value per share
—
—
9.09
6.77
11.14
18.7
51.42
Working capital per share
—
—
6.45
5.48
5.9
9.33
28.04
Book value per share
—
—
9.09
6.77
11.14
18.7
51.42
Nouvelles
Kymera Q4 Loss Wider Than Expected, Cash Boost Extends Runway
Morgan Stanley réduit l’objectif de cours de Kymera Therapeutics
Morgan Stanley cuts Kymera Therapeutics stock price target on pipeline progress
RBC Capital relève l’objectif de cours de Kymera Therapeutics
RBC Capital raises Kymera Therapeutics price target on pipeline progress
RBC Capital raises Kymera Therapeutics price target on pipeline
Stifel réitère sa recommandation d’achat sur Kymera Therapeutics à 114$
Stifel reiterates Buy rating on Kymera Therapeutics stock at $114
Kymera Q4 2025 slides: pipeline advances despite revenue miss
Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates
Kymera Therapeutics lance une offre d’actions de 500 millions de dollars
Kymera Therapeutics launches $500 million at-the-market stock offering